Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development
被引:37
作者:
Guo, J
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
Guo, J
de Waard, V
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
de Waard, V
论文数: 引用数:
h-index:
机构:
Van Eck, M
Hildebrand, RB
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
Hildebrand, RB
van Wanrooij, EJA
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
van Wanrooij, EJA
Kuiper, J
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
Kuiper, J
Maeda, N
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
Maeda, N
Benson, GM
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
Benson, GM
Groot, PHE
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
Groot, PHE
Van Berkel, TJC
论文数: 0引用数: 0
h-index: 0
机构:Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
Van Berkel, TJC
机构:
[1] Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands
[2] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA
[3] GlaxoSmithKline, Atherosclerosis Dept, Stevenage, Herts, England
bone marrow transplantation;
CCR2;
regression of atherosclerosis;
D O I:
10.1161/01.ATV.0000163181.40896.42
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective - Using bone marrow transplantation, we have previously demonstrated the critical role that hematopoietic CCR2 plays in early atherogenesis. Reconstitution of irradiated apolipoprotein (apo) E3-Leiden mice with CCR2-deficient bone marrow progenitor cells resulted in 86% reduction on overall atherosclerotic lesion development. However, no data on CCR2 in the cause of established atherosclerosis have been reported so far. Methods and Results - To study the role of CCR2 in established atherosclerotic lesions, bone marrow progenitor cells harvested from apoE(-/-) and apoE(-/-)/CCR2(-/-) mice were transplanted into lethally irradiated 16-week-old apoE(-/-) mice with established atherosclerotic lesions. No significant differences were found in serum total cholesterol and triglycerides levels at different time points after transplantation. At age 16 weeks, lesion size in control apoE(-/-) mice was 3.28 +/- 1.06 x 10(5) mu m(2). At 9 weeks after transplantation, apoE(-/-) --> apoE(-/-) and apoE(-/-)/ CCR2(-/-) --> apoE(-/-) mice had developed significantly larger atherosclerotic lesions (4.49 +/- 0.92 x 10(5) mu m(2), P < 0.02 and 4.15 +/- 0.62 x 10(5) mu m(2), P < 0.04 compared with controls, respectively). However, no significant effect of disruption of hematopoietic CCR2 was observed on the progression of lesions. Furthermore, the macrophage positive area ( 78 +/- 4% versus 72 +/- 9%) and collagen content ( 11 +/- 6% versus 15 +/- 3%) of the lesions were similar as well. Conclusion - In contrast to the critical role of CCR2 in the initiation of atherogenesis, bone marrow progenitor cell-derived CCR2 does not influence the progression of established atherosclerotic lesions, pointing to additional mechanisms for recruitment of monocytes at later stages of lesion development.